🌟 The Japan Patent Office has issued a Notice of Allowance for our ExoPTEN patent! 🌟 This milestone expands our coverage in a crucial market, supporting our innovative therapy aimed at promoting nerve growth and regeneration after spinal cord injury. #NurExone #Biotech #ExoPTEN #RegenerativeMedicine #Patent #SpinalCordInjury #Innovation #Japan #CNSRecovery https://lnkd.in/dAfpxeXZ
NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90)
Biotechnology Research
Regenerate - Rewire - Recover
About us
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
- Website
-
https://nurexone.com
External link for NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90)
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Haifa
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Haifa, IL
Employees at NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90)
-
Yossi Mograbi
-
Sharon Soueid-Baumgarten
Senior Scientist at NurExone Biologic
-
Lior Shaltiel, PhD
Chief Executive Officer at NurExone Biologic (TSXV:NRX)(OTCQB:NRXBF)(FSE:J90) | Senior Lecturer (of the practice) Head of the BioMed-MBA program at…
-
Kineret Taler
Preclinical Study Manager at NurExone Biologic
Updates
-
Q1 analyst report and reiterated Buy Rating from Litchfield Hills Research, LLC. As highlighted in the latest report, we are on track with key milestones, including expanded preclinical testing for ExoPTEN for acute spinal cord injury, expanded lab space space, new hires to boost strategic collaborations, and broadening our U.S. market reach with an OTCQB listing. #biotech #innovation #growth #NRX #milestones #BuyRating
-
Watch an in-depth webinar featuring a corporate presentation and Q&A session with Lior Shaltiel, PhD focused on financial market questions Thanks to Dr. Eva Reuter for hosting! https://lnkd.in/eGxPDhc8
29/5 Webinar Hosted by Dr. Reuter Investor Relations
https://www.youtube.com/
-
Lior Shaltiel, PhD will be speaking on the topic of "Revolutionizing Spinal Cord Injury" at #ExosomesEurope in #London on June 5-6. Terrific opportunity to connect with fellow experts and executives, and to contribute to the advancement of healthcare. #ExosomesEurope #EVProducts #ClinicalStage #Commercialization #Innovation #HealthcareAdvancements #Spinalhealth https://lnkd.in/daMF7yDF
Lior Shaltiel - NurExone Biologic | Exosomes Europe Speaker
informaconnect.com
-
https://lnkd.in/d4twTa4B Q1 2024 financial and operational results as we advance towards human trials with ExoPTEN. Stay tuned for more updates as we pioneer regenerative medicine and expand our ExoTherapy platform! #Biotech #RegenerativeMedicine #Innovation #spinalhealth
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
globenewswire.com
-
The distinguished past and exciting future expected for NurExone's groundbreaking technology are detailed in this article in TheMarker, a leading business journal in Israel (Hebrew only). Shulamit Levenberg Lior Shaltiel, PhD Yoram Drucker Daniel Offen #technioninnovation #exotherapy #regenerativemedicine #spinehealth
-
https://lnkd.in/d3vHCfUs Welcoming Dr. Ram Petter as a strategic consultant to drive biopharma and biotech collaborations for our #ExoTherapy platform #NurExone #Biopharma #RegenerativeMedicine #ExoTherapy #StrategicPartnerships #Innovation #Healthcare
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
globenewswire.com
-
Our Dr. Ina Sarel leading an insightful and successful workshop on regulatory challenges in product development at the #Exosome Characterization & Analytical Development Summit in #Boston. Well done Ina Sarel! #exosomeexperts #newconnections #goodscience Dr. Carla Mazzeo Katie Gilligan Khadija Abi Nader
-
Morningstar assigned a quantitative stock rating for Nurexone Biologic! Exciting times ahead in regenerative medicine for spinal cord injury. #NurexoneBiologic #Morningstar #regenerativemedicine https://lnkd.in/djJ82HmW
Morningstar Quant Report
nurexone.com
-
🌟 NurExone Expanding to US Financial Markets with OTCQB Listing Approval and DTC Eligibility 🌟 Shares trading under the symbol NRXBF. #USmarketaccess #biopharmaceutical #OTCQB #DTC #innovation https://lnkd.in/dz9xEM8G
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
globenewswire.com